CELL INTELLIGENCE · 肿瘤细胞治疗研究

靶向 B7-H3-CAR-T 细胞中的 Regnase-1 重编程肿瘤微环境并增强骨肉瘤抗肿瘤疗效

Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma.

骨肉瘤“冷转热”的概念蓝图：从肿瘤微环境分层假说到适应性治疗前景

A conceptual blueprint for "turning cold to hot" in Osteosarcoma: from TME stratification hypotheses to adaptive therapeutic prospects.

骨肉瘤的基因免疫治疗：从溶瘤载体到工程化免疫细胞

Gene-based immunotherapy in osteosarcoma: from oncolytic vectors to engineered immune cells.

重编程过继细胞治疗骨肉瘤：工程化、疫苗接种与肿瘤微环境重塑

Reprogramming adoptive cell therapy for osteosarcoma: engineering, vaccination, and tumor microenvironment remodeling.

RAE1 装甲 DC 疫苗增强 NKG2D-CAR-T 细胞诱导的抗实体瘤治疗

RAE1-armoured DC vaccine boosts NKG2D-CAR-T cells elicited anti-solid tumour treatment.

NKG2D GD2NK 细胞治疗神经母细胞瘤、骨肉瘤：I 期临床试验（Baylor College of）

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

这是一项 I 期注册临床试验，评估 GD2NK 细胞治疗神经母细胞瘤、骨肉瘤的疗效与安全性。当前状态：招募中。计划入组 27 例。试验地点：美国 · 休斯顿（共 1 个中心）。登记号：NCT07211737。

骨肉瘤免疫治疗进展

Advances on immunotherapy for osteosarcoma.

肉瘤细胞治疗的演变：突破、挑战与未来方向

The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions.

儿童骨肉瘤的免疫治疗：当前进展与未来方向

Immunotherapy in pediatric bone sarcomas: Current progress and future directions.

CAR-CIK 对比 CAR-T：新型细胞因子诱导的杀伤细胞在 ErbB2⁺ 横纹肌肉瘤中作为实体瘤免疫治疗的基准评估

CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.

我们的结果表明，CAR-CIK 细胞至少与 CAR-T 细胞效力相当。结合其良好的安全性特征和异体应用可行性，这些发现使 CAR-CIK 细胞成为实体瘤有前景的免疫效应细胞。